Introduction
Small bowel transplantation (SBT) can induce two types of immune reaction in graft recipients: host-versus-graft reaction (HVGR or rejection) and graft-versus-host reaction (GVHR). Prevention of both reactions is a key requirement for successful transplantation. 1 Previous studies have reported that the powerful immunosuppressive agent FK506 could control GVHR in experimental and clinical SBT studies, 2, 3 and therefore the greatest threat to graft survival is the rejection response. Patients with short bowel syndrome are increasingly treated with SBT 4 and immunosuppressive drugs, 5 but rejection is still more difficult to control after SBT than after other solid organ transplants, 6 a factor which limits its use.
The increased demand for grafts makes Donor-specific immunosuppression is important in transplant surgery. We examined the effect of intraportal donorspecific bone marrow transplantation on heterotopic small bowel transplantation in the high responder rat combination, ACI to Lewis. The study comprised five treatment groups: untreated controls (group 1); FK506 alone (group 2); low-dose predonine + FK506 (group 3); high-dose predonine + FK506 (group 4); and intraportal donorspecific bone marrow transplantation + FK506 (group 5). Intraportal transplantation was performed pre-operatively and FK506 and predonine given postoperatively. Intestinal allograft survival and changes of intragraft cytokine expression were analysed using the reverse transcription polymerase chain reaction. Allograft survival (mean ± SD) was lowest in group 1 and greatest in group 5. The group 5 treatment regimen also downregulated interferon-g and interleukin-2 transcription in the transplanted intestine. Intraportal donor bone marrow transplant combined with FK506 immunosuppression was found therefore to be the most beneficial treatment regimen DS Sun, T Yagi, T Oyama et al.
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matching for size and cytomegalovirus (CMV) status more difficult. 4 The use of living donors could increase donor supply, allow for earlier transplantation, and may be immunologically beneficial. Previous studies using segmental SBT in animal models have demonstrated graft function adequate for good nutrition and postoperative growth, and are encouraging. 7 There is growing evidence however, that tacrolimus (FK506), the primary immunosuppressant used for SBT, causes significant impairment in metabolic function in transplant patients. 8, 9 Steroid hormones have profound anti-inflammatory and immunosuppressive actions and are central to clinical therapy of inflammatory and autoimmune diseases affecting humoral and cell-mediated immunity. 10, 11 The clinical outcome of solid organ transplants has improved dramatically since the introduction of FK506 and steroids (FK506-based double therapy). Lifethreatening complications (such as systemic sepsis and related death), however, remain serious complications of non-specific immunosuppressant use, especially in SBT. The most desirable immunosuppression in SBT is induction of donor-specific immune hyporesponsiveness or tolerance. Recent attempts have refocused on the simultaneous administration of donor cells and organ transplantation under FK506based immunosuppression for immune ablation.
We have previously demonstrated the beneficial effects of intraportal donor-specific bone marrow transplantation (DSBMT-PV) in SBT. 12 This study evaluates the effects of DSBMT-PV under FK506-based immunosuppression on rat heterotopic SBT in a highresponder combination, compared with FK506-based double therapy.
Materials and methods

ANIMALS
Inbred adult male ACI (MHC haplotype, RT1 avl ) and Lewis (RT1 l ) rats were purchased from the Seiwa Experimental Farm (Fukuoka, Japan), and maintained at the Animal Centre of Okayama University Medical School on a standard diet. ACI and Lewis rats, weighing 200 -300 g, were used as donors and recipients, respectively, for organ transplantation. Ethical approval for the study was obtained from the Animal Centre for Medical Research.
EXPERIMENTAL DESIGN
Rats were assigned to the five groups according to the immunosuppressive schedule: i) Untreated Lewis rats receiving an ACI intestinal graft, control group (group 1, n = 5); ii) Recipients treated with 0.5 mg/kg FK506 between day 0 and day 4 after SBT (group 2, n = 5); iii) Recipients treated with 0.5 mg/kg FK506 and low-dose (0.5 mg/kg) predonine between day 0 and day 4 (group 3, n = 5); iv) Recipients treated with 0.5 mg/kg FK506 and high-dose (5.0 mg/kg) predonine between day 0 and day 4 (group 4, n = 5); v) Recipients treated with DSBMT-PV preoperatively (day 0) and 0.5 mg/kg FK506 between day 0 and day 4 after SBT (group 5, n = 5).
SMALL BOWEL TRANSPLANTATION
Heterotopic small bowel transplantation was performed using a modification of the method described by Kobayashi et al. 13 Briefly, the donor was given 100 IU heparin intravenously, and a 10 -15 cm segment of distal ileum was harvested, with the vascular pedicle of the portal vein attached, and an aortic cuff applied to the superior mesenteric
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artery. The small bowel lumen was flushed with saline and stored in crushed ice saline solution while the recipient was prepared. The donor superior mesenteric artery, with aortic cuff, and the portal vein were anatomized to the recipient's left renal artery and vein, respectively, using a cuff technique. The graft ends were exteriorized and sutured to the abdominal wall as an ileostomy, and the abdomen closed. Total ischaemic time ranged from 30 min to 45 min and no antibiotics were administered.
PREPARATION OF BONE MARROW CELLS AND BONE MARROW TRANSPLANTATION
Bone marrow cells were obtained from the femur and tibia of ACI rats. Red blood cells were lysed for 5 min with Tris-NH 4 Cl, and bone marrow cells washed twice, counted, and adjusted to a concentration of 5 × 10 7 cells/ml. Cell viability was determined by trypan blue exclusion as greater than 95%. Cells were peri-operatively injected through the portal vein, using a 27-gauge needle. The needle was rapidly withdrawn after injection, and haemostasis without haematoma formation achieved by gentle pressure with a cotton wool swab.
FK506 AND PREDONINE TREATMENTS
FK506 (Fujisawa Pharmaceutical Co., Ltd, Osaka, Japan) and predonine (predonisone, Shionogi Pharmaceutical Co., Ltd, Osaka, Japan) were dissolved in saline solution and injected intramuscularly. The dose and period of administration are described in the experimental design section.
ASSESSMENT OF GRAFT SURVIVAL AND GRAFT-VERSUS-HOST DISEASE
Graft survival was monitored daily by palpation of the graft for induration, and examination of the stomas. Rejection was confirmed by histological examination of a stoma biopsy. Examination for signs of GVHD, including skin rash, hair loss, unkempt appearance, diarrhoea and weight loss was also performed.
REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION FOR CYTOKINE EXPRESSION IN THE GRAFT
The graft specimens, including whole layers of intestine from the stoma, were obtained on day 3, day 7 and day 10 following surgery, and were immediately frozen in liquid nitrogen and stored at -80 o C. Snap-frozen specimens were pulverized, and total RNA extracted using a guanidinium isothiocyanate/phenol/chloroform procedure (RNAzol B, Tel-Test, Friendswood, TX, USA). Isolated RNA was air-dried and resuspended in RNase free water, and the quantity and purity determined by optical density. RNA was considered pure if the O.D. 260/280 ratio was > 1.7. First-strand cDNA synthesis used 2 µg total RNA, 1.2 µg oligo(dT), 15 IU RNAsin (Promega, Madison, WI, USA) and 400 IU Maloney murine leukaemia virus reverse transcriptase (Bethesda Research Laboratories, Bethesda, MD, USA) in a 40 µl reaction volume, according to the manufacturer's instructions. Gene-specific primer sequences, as shown in Table 1 , were selected from separate exons and synthesized as previously reported. 13 In each 50 µl amplification reaction, 2 µl of first strand cDNA product was used. To reduce background amplification, polymerase chain reaction master mixture 
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the double-stranded DNA, samples were heated to 95 o C for 10 min prior to cycling. Amplification was performed as described in Table 2 , followed by a single 7 min extension at 75 o C using a DNA thermal cycler (Gene Amp PCR system 9600, Perkin-Elmer Corp., Hayward, CA, USA). Amplification products were visualized by ethidium bromide-stained (10 µl) agarose gel electrophoresis. All PCR results were representative of three separate experiments, each performed using RNA obtained from a pool of grafts from three to six rats, unless specifically noted.
MIXED LYMPHOCYTE REACTION ASSAY
Stimulator cells, comprising peripheral blood lymphocytes (PBLs) obtained from ACI rats, were treated with 5% mitomycin C (MMC, Kyowa Hakko Co., Ltd, Tokyo, Japan) in RPMI-1640 medium at 37 o C for 40 min. Responder cells, PBLs from recipient Lewis rats prepared on day 5 after SBT, were incubated with γ-irradiated stimulator cells (3000 rad from a 137 Cs source), and cultured in 96-well flat-bottomed plates in triplicate (3 × 10 5 cells/ 100 µl per well) with an equal number of MMC-treated stimulator cells. Plates were incubated at 37 o C in 5% CO 2 for 4 days, then pulse-labelled for 18 h with 3 H thymidine (1 µCi/well) and harvested. Proliferation was assayed by 3 H thymidine incorporation measured using a liquid scintillation counter (Aloka Co., Ltd, Tokyo, Japan).
STATISTICS
Data are expressed as the mean ± SD, and were analysed by unpaired Student's t-test. P < 0.05 was considered to be significant. 
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Results
EFFECT OF TREATMENT WITH FK506, STEROIDS OR BONE MARROW TRANSPLANTATION ON GRAFT SURVIVAL AFTER SMALL BOWEL TRANSPLANTATION
Graft survival times are summarized in Table 3 . The treatments received by group 2, group 3, group 4 and group 5 significantly prolonged graft survival time compared with the control group (group 1; P < 0.01). The most beneficial immunosuppression was achieved with the DSBMT-PV/FK506 treatment regimen (group 5), and graft survival in group 5 was significantly prolonged compared with group 4 (P < 0.01). No GVHD was observed in any animal.
INTRAGRAFT CYTOKINE EXPRESSION AS DETERMINED BY RT-PCR
Changes in intragraft cytokine expression by group are shown in Fig. 1 . All mRNAs were expressed on day 3 in the control group (group 1). Expression of interferon (IFN)-γ and interleukin-2 mRNA was undetectable in group 5 until day 10, and in group 4 on day 7. Both were detected in group 2 and group 3 at all measurement times. Expression of IL-10 mRNA was detectable at all times measured in group 5, but only on day 3 and day 7 in groups 2 -4. IL-18 mRNA was expressed continually, with no significant difference between groups.
EFFECT OF THE TREATMENT REGIMENS ON MIXED LYMPHOCYTE REACTION ASSAY
The results of the mixed lymphocyte reaction assay, on day 5, are shown in Table 4 . Significant suppression was observed in group 2 and group 5, compared with group 1 (P < 0.01) and in group 5 compared with group 2 (P < 0.01).
Discussion
This study demonstrates that treatment with DSBMT-PV plus FK506 significantly prolongs intestinal allograft survival compared with conventional FK506-based therapy with or without steroids. Infection-related deaths are frequent in patients with chronic high-dose steroid exposure, 14 emphasizing the benefit, in SBT, of DSBMT-PV plus FK506, without pre-sensitization.
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Long-term survival of intestinal allografts was obtained by portal venous donor-specific cell inoculation, not by systemic venous transfusion. 12, 17 The mechanism of PV injection of allogenic cells is, however, still under debate. Unresponsiveness, induced by PV injection of allogenic cells, was maintained by clonal anergy, with defective co-stimulation between donor and donorspecific recipient CD8 + T cells. 18 Kupffer cells in the liver are thought to be important for graft enhancement, via manipulation of arachidonic acid metabolism. 19 Production of T helper 2 (Th2) cytokines by recipient γδ T cells following PV pre-transplant preimmunization is another possible mechanism for immunosuppression, 20 as cytokines play an important role in immune responses. Mechanisms of transplanted organ rejection, including the role of cytokines, are well classified. T Helper 1 (Th1) cells, which produce IFN-γ and IL-2, are dominant in the rejection reaction, while Th2 cells are involved in tolerance maintenance. 21 Recent observations revealed an unusual pattern of cytokine expression during rejection of allo-intestinal grafts in experimental SBT. IFN-γ was detected early in rejection, without clinical symptoms, and levels progressively increased with time. 12,13 IFN-γ is therefore an important immune mediator of graft rejection in SBT. 22 The effect of IFN-γ may result from reduced intestinal barrier function, because the resistance on tight junctions is diminished by a direct biological effect of IFN-γ. 23 Interferon-γ inhibits proliferation of jejunal smooth muscle cells as well, 24 and activates the cytotoxic potential of macrophages. 25 Persistent elevation of IFN-γ may therefore cause significant damage to epithelial integrity. A short-term blockade of the IL-2 pathway often results in tolerance in experimental models, 26 suggesting that IL-2 is responsible for IFN-γ production. IL-18 is a recently-discovered IFN-γ-inducing factor (IGIF), produced mainly by macrophages and known as a pro-inflammatory cytokine. A treatment regimen which effectively suppresses production of IL-2 and IL-18 in grafts could result in significant prolongation of intestinal allograft survival.
We studied the effect of treatment with FK506, steroids and BMT on intragraft cytokine expression. A combination of DSBMT-PV plus low-dose FK506 effectively suppressed IFN-γ and IL-2 expression on all measurement days, while FK506 plus a highdose steroid achieved only temporary suppression. None of the treatments suppressed IL-18 expression, suggesting that IL-18 may not be responsible for IFN-γ production in intestinal allograft. All treatments, except DSBMT-PV plus low-dose FK506, suppressed expression of IL-10 by day 10, implying that IL-10 played a role in preventing rejection.
Mixed lymphocyte reaction assays in group 5 were remarkably suppressed compared with group 2. The concept of immunological ablation or cytoreduction with haematopoietic reconstitution arose from the original demonstration that infusion of replicating donor haematopoietic cells into naturally immunologically incompetent neonates induces tolerance. 27 This infusion led to adult chimerism and donor-specific allograft tolerance (termed actively acquired tolerance) and suggests that tolerance, like rejection, involves an active immune response of alloreactive cells to specific donor antigens.
Recent reports have documented the fact that steroids, although effective in blocking rejection, counteract the active immune pathways, leading to tolerance. 28 There is also growing clinical and experimental evidence to suggest that steroids block tolerance under certain circumstances. 29 Steroids can therefore have deleterious and advantageous effects when used in immunomodulatory strategies, such as donor-specific blood transfusions (DSBT). Adjunction of steroids with DSBT triggers accelerated acute rejection in experimental SBT. 30 As mentioned earlier, steroids can increase infection-related deaths 14 which, together with their tolerance-blocking action, may reduce their suitability as immunosuppressive agents.
Our study found that augmentation of DSBMT with low-dose FK506 was the best treatment regimen for SBT. We believe that clinical application of this regimen is warranted, but further research on operating mechanisms is needed. 
288
